Zimmer Biomet Holdings AI Stock Analysis
Want to see ZBH full AI Analyst Report?
Zimmer Biomet Holdings (ZBH) AI Stock Analysis
Zimmer Biomet Holdings
(NYSE:ZBH)
ZBH scores positively on fundamentals and the latest earnings update: revenue growth, durable cash generation, and raised 2026 guidance with significant buybacks support the outlook. The technical picture is strong but overbought, which raises near-term volatility risk. The main drag on the score is valuation (higher P/E with a low dividend yield) alongside ongoing margin pressure, knee franchise weakness, and China headwinds.
Zimmer Biomet Holdings Key Performance Indicators (KPIs)
Revenue by GeographyBreaks down revenue across different regions, revealing where the company is strongest and where it may face risk or growth potential due to local economic conditions or market share shifts.
U.S. sales are clearly the growth engine—steadier and accelerating into 2026—while international revenues are more volatile and still grappling with China and emerging‑market weakness. Management’s raised guidance and strong U.S. organic growth reflect hip, robotics, and Paragon contributions (Paragon adds ~110bps), but international recovery is uneven and supply constraints/price pressure could limit upside. For investors, the story is U.S.-led marginable growth and cash-funded buybacks, with international execution and pricing erosion the main near‑term risks to sustain momentum.
Zimmer Biomet Holdings (ZBH) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $19.32B
- Dividend Yield
- 0.94%
- Average Volume (3M)
- 2.10M
- Price to Earnings (P/E)
- 25.9
- Beta (1Y)
- 0.29
- Revenue Growth
- 6.98%
- EPS Growth
- -2.22%
- Country
- US
- Employees
- 17,000
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
Zimmer Biomet Holdings Business Overview & Revenue Model
Company Description
Zimmer Biomet Holdings, Inc. engages in the design, manufacture, and marketing of orthopedic reconstructive products. The firm also offers sports medicine, biologics, extremities, and trauma products, spine, craniomaxillofacial, and thoracic products...
How the Company Makes Money
Zimmer Biomet makes money primarily by selling orthopedic implants, surgical instruments, and related enabling technologies to healthcare providers, with revenue recognized from product sales through a combination of direct sales forces and distribut...
Zimmer Biomet Holdings Earnings Call Summary
The call was broadly positive. Zimmer Biomet reported solid third-quarter growth, strong performance across Hips, S.E.T. and technology, significant cash generation, progress in its commercial transformation and multiple increases to its 2026 outlook. The main challenges were declining knee sales, China-related headwinds, margin pressure from manufacturing costs and ongoing investment in the U.S. sales force. Management expressed confidence in the long-term strategy and expects improved knee performance and additional growth catalysts in 2027.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Zimmer Biomet raised its 2026 organic constant currency sales growth guidance to a range of 3% to 3.5% from 2.25% to 3.25%, adjusted earnings per share guidance to $8.50 to $8.60 from $8.47 to $8.59, and reported sales growth guidance to 4.4% to 4.9% from 3.9% to 4.9%; foreign exchange is expected to be an approximate 25 basis point tailwind, Paragon 28 to contribute 110 basis points, China-related headwinds to total nearly 100 basis points in the fourth quarter and roughly 50 basis points for the full year 2026, adjusted gross margin to be around 72%, adjusted operating margin to decline a little more than 50 basis points year-over-year, net interest and other nonoperating expenses to be $300 million, the adjusted tax rate approximately 18%, share repurchases approximately $1 billion, fully diluted weighted average shares around 193 million, and free cash flow to grow 9% to 11%; pricing is expected to be flat to 100 basis points of pressure, the company aspires to a 6% WAMGR by the end of the decade, expects 2027 to be a better year compared to 2026, and anticipates Monogram can launch in the first half of 2027, pending approval.
Zimmer Biomet Holdings Financial Statement Overview
Summary
Solid business quality with rising revenue and generally healthy profitability, supported by durable free cash flow that exceeds net income in the TTM. Offsets include margin compression versus 2023–2024 highs, choppy free cash flow growth, and moderately higher leverage versus prior years.
Income Statement
72PositiveBalance Sheet
68PositiveCash Flow
63Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 8.57B | 8.23B | 7.68B | 7.39B | 6.94B | 6.83B |
| Gross Profit | 5.97B | 5.07B | 5.49B | 5.31B | 4.92B | 4.87B |
| EBITDA | 2.29B | 2.22B | 2.25B | 2.22B | 1.49B | 1.65B |
| Net Income | 767.50M | 705.20M | 903.80M | 1.02B | 231.40M | 401.60M |
Balance Sheet | ||||||
| Total Assets | 23.54B | 23.09B | 21.37B | 21.50B | 21.07B | 23.46B |
| Cash, Cash Equivalents and Short-Term Investments | 399.90M | 591.90M | 525.50M | 415.80M | 375.70M | 378.10M |
| Total Debt | 7.50B | 7.52B | 6.20B | 5.77B | 5.70B | 7.07B |
| Total Liabilities | 10.81B | 10.39B | 8.89B | 9.01B | 9.04B | 10.79B |
| Stockholders Equity | 12.73B | 12.70B | 12.47B | 12.48B | 12.02B | 12.66B |
Cash Flow | ||||||
| Free Cash Flow | 1.66B | 1.47B | 1.14B | 1.19B | 1.07B | 1.35B |
| Operating Cash Flow | 1.88B | 1.70B | 1.50B | 1.58B | 1.28B | 1.50B |
| Investing Cash Flow | -1.22B | -1.98B | -888.10M | -778.90M | -529.20M | -503.60M |
| Financing Cash Flow | -1.56B | 326.00M | -484.50M | -763.50M | -843.80M | -1.31B |
Zimmer Biomet Holdings Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ZBH, the sentiment is Positive. The current price of 102.09 is above the 20-day moving average (MA) of 101.27, above the 50-day MA of 95.92, and above the 200-day MA of 92.31, indicating a bullish trend. The MACD of 2.54 indicates Positive momentum. The RSI at 53.60 is Neutral, neither overbought nor oversold. The STOCH value of 25.81 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ZBH.
Zimmer Biomet Holdings Risk Analysis
Zimmer Biomet Holdings disclosed 32 risk factors in its most recent earnings report. Zimmer Biomet Holdings reported the most risks in the "Legal & Regulatory" category.
Latest Risks Added
3 New RisksZimmer Biomet Holdings Peers Comparison
Overall Rating
MDT81Outperform
SYK75Outperform
GMED73Outperform
SNN69Neutral
ZBH69Neutral
BVS66Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 81Outperform | $130.88B | 25.13 | 10.60% | 2.80% | 9.77% | 12.28% | |
| 75Outperform | $120.88B | 33.61 | 15.61% | 1.11% | 7.87% | 22.82% | |
| 73Outperform | $9.27B | 16.99 | 11.82% | ― | 13.35% | 32.22% | |
| 69Neutral | $12.72B | 20.02 | 12.25% | 2.60% | 5.26% | 31.02% | |
| 69Neutral | $19.32B | 25.92 | 6.05% | 0.94% | 6.98% | -2.22% | |
| 66Neutral | $893.17M | 12.42 | 27.23% | ― | 3.87% | 623.68% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| ZBH | Zimmer Biomet Holdings | 102.09 | 13.59 | 15.35% | |
| MDT | Medtronic | 102.32 | 5.20 | 5.35% | |
| SNN | Smith & Nephew Snats | 30.51 | -0.95 | -3.01% | |
| SYK | Stryker Corp | 317.54 | -42.70 | -11.85% | |
| GMED | Globus Medical | 69.99 | -13.83 | -16.50% | |
| BVS | Bioventus, Inc. | 10.60 | 3.88 | 57.74% |
Zimmer Biomet Holdings Corporate Events
Zimmer Biomet Restructures Leadership to Boost U.S. Growth
PositiveOn September 8, 2026, Zimmer Biomet announced a restructuring of its Americas and Global Business Group leadership, promoting Gary Campbell to President, Americas, Brian Hatcher to President, Recon, S.E.T., CMFT, Neuro and Biosurgery, and Bradley Kes...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 05, 2026
